FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder
The FDA has approved Ultomiris for patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 (AQP4) antibody positive.
Source: neurologyadvisor.com
Page 9 - Boxed Warning News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Boxed Warning Today - Breaking & Trending Today
Vafseo Approved for Anemia Due to CKD in Patients on Dialysis
Vafseo is an oral reversible inhibitor of hypoxia-inducible factor (HIF)-prolyl-4-hydroxylases (PH)1, PH2, and PH3.
Source: empr.com
FDA Approves Johnson & Johnson OPSYNVI (macitentan and tadalafil) Single-Tablet Combination for Patients with Pulmonary Arterial Hypertension (PAH)
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI for the chronic treatment of adults with pulmonary arterial hypertension (PAH). The newly-approved drug is a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor.
Source: dicardiology.com
FDA approves J&J's OPSYNVI for pulmonary arterial hypertension patients
In a significant milestone for pulmonary arterial hypertension (PAH) patients, Johnson & Johnson has announced the approval of OPSYNVI.
Source: outsourcing-pharma.com
FDA Approves Macitentan, Tadalafil Combination Tablet for Pulmonary Arterial Hypertension
The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study.
Source: ajmc.com